Ton N M Schumacher

List of Publications by Year
in descending order

307	63,621	2802	962
papers	citations	94 h-index	238 g-index

329	329	329	65142
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Signatures of mutational processes in human cancer. Nature, 2013, 500, 415-421.	27.8	8,060
2	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. Science, 2015, 348, 124-128.	12.6	6,756
3	Neoantigens in cancer immunotherapy. Science, 2015, 348, 69-74.	12.6	3,809
4	Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. New England Journal of Medicine, 2016, 375, 819-829.	27.0	2,430
5	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 2014, 515, 577-581.	27.8	1,705
6	The Human Cell Atlas. ELife, 2017, 6, .	6.0	1,547
7	Regulation and Function of the PD-L1 Checkpoint. Immunity, 2018, 48, 434-452.	14.3	1,437
8	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	27.8	1,421
9	Synergism of Cytotoxic T Lymphocyteâ€“Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses. Journal of Experimental Medicine, 2001, 194, 823-832.	8.5	959
10	Empty MHC class I molecules come out in the cold. Nature, 1990, 346, 476-480.	27.8	905
11	Defining â€˜T cell exhaustionâ€™. Nature Reviews Immunology, 2019, 19, 665-674.	22.7	879
12	T Cell Dysfunction in Cancer. Cancer Cell, 2018, 33, 547-562.	16.8	787
13	A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nature Medicine, 2018, 24, 994-1004.	30.7	783
14	CD8+ T cell states in human cancer: insights from single-cell analysis. Nature Reviews Cancer, 2020, 20, 218-232.	28.4	766
15	Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell, 2019, 176, 775-789.e18.	28.9	760
16	Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma. Journal of Clinical Oncology, 2013, 31, e439-e442.	1.6	746
17	Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nature Medicine, 2020, 26, 566-576.	30.7	736
18	CD27 is required for generation and long-term maintenance of T cell immunity. Nature Immunology, 2000, 1, 433-440.	14.5	662

#	Article	IF	Citations
19	The â€œcancer immunogramâ€• Science, 2016, 352, 658-660.	12.6	655
20	Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell, 2018, 174, 1586-1598.e12.	28.9	644
21	Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nature Medicine, 2018, 24, 1655-1661.	30.7	599
22	High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nature Medicine, 2015, 21, 81-85.	30.7	594
23	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nature Medicine, 2019, 25, 920-928.	30.7	589
24	Guidelines for the use of flow cytometry and cell sorting in immunological studies[*]. European Journal of Immunology, 2017, 47, 1584-1797.	2.9	505
25	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature, 2017, 549, 106-110.	27.8	501
26	Skin-resident memory CD8 ⁺ T cells trigger a state of tissue-wide pathogen alert. Science, 2014, 346, 101-105.	12.6	444
27	CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Medicine, 1999, 5, 774-779.	30.7	439
28	Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell, 1990, 62, 563-567.	28.9	415
29	Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science, 2016, 352, 1337-1341.	12.6	414
30	Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nature Medicine, 2019, 25, 89-94.	30.7	413
31	Towards error-free profiling of immune repertoires. Nature Methods, 2014, 11, 653-655.	19.0	411
32	Neoantigen landscape dynamics during human melanomaâ€“T cell interactions. Nature, 2016, 536, 91-95.	27.8	387
33	Cancer Neoantigens. Annual Review of Immunology, 2019, 37, 173-200.	21.8	384
34	Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nature Medicine, 2010, 16, 565-570.	30.7	381
35	TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell, 1993, 74, 577-584.	28.9	348
36	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 948-960.	10.7	346

#	Article	IF	Citations
37	Diverse and heritable lineage imprinting of early haematopoietic progenitors. Nature, 2013, 496, 229-232.	27.8	337
38	Identification of D-Peptide Ligands Through Mirror-Image Phage Display. Science, 1996, 271, 1854-1857.	12.6	330
39	Antiâ€“CTLA-4 therapy broadens the melanoma-reactive CD8 ⁺ T cell response. Science Translational Medicine, 2014, 6, 254ra128.	12.4	325
40	Heterogeneous Differentiation Patterns of Individual CD8 ⁺ T Cells. Science, 2013, 340, 635-639.	12.6	320
41	Adoptive cellular therapy: A race to the finish line. Science Translational Medicine, 2015, 7, 280ps7.	12.4	320
42	Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature, 2019, 572, 538-542.	27.8	312
43	Functional heterogeneity of human memory CD4 ⁺ T cell clones primed by pathogens or vaccines. Science, 2015, 347, 400-406.	12.6	309
44	Design and use of conditional MHC class I ligands. Nature Medicine, 2006, 12, 246-251.	30.7	304
45	Tertiary lymphoid structures in cancer. Science, 2022, 375, eabf9419.	12.6	303
46	Generation of peptideâ€“MHC class I complexes through UV-mediated ligand exchange. Nature Protocols, 2006, 1, 1120-1132.	12.0	293
47	The CD47-SIRPÎ± Immune Checkpoint. Immunity, 2020, 52, 742-752.	14.3	291
48	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell, 2020, 183, 818-834.e13.	28.9	287
49	Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nature Methods, 2009, 6, 520-526.	19.0	286
50	In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nature Medicine, 2002, 8, 410-414.	30.7	275
51	Immunotherapy through TCR gene transfer. Nature Immunology, 2001, 2, 957-961.	14.5	271
52	Primary T Cell Expansion and Differentiation In Vivo Requires Antigen Presentation by B Cells. Journal of Immunology, 2006, 176, 3498-3506.	0.8	266
53	Peptide contributes to the specificity of positive selection of CD8+ T cells in the thymus. Cell, 1993, 73, 1041-1049.	28.9	261
54	Peptide selection by MHC class I molecules. Nature, 1991, 350, 703-706.	27.8	257

#	Article	IF	Citations
55	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 449-58.	4.2	253
56	T-cell-receptor gene therapy. Nature Reviews Immunology, 2002, 2, 512-519.	22.7	246
57	Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nature Medicine, 2020, 26, 1839-1844.	30.7	245
58	Antigen receptor repertoire profiling from RNA-seq data. Nature Biotechnology, 2017, 35, 908-911.	17.5	243
59	Tissue-resident memory CD8 ⁺ T cells continuously patrol skin epithelia to quickly recognize local antigen. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19739-19744.	7.1	230
60	Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell, 2018, 172, 549-563.e16.	28.9	226
61	Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator.. Journal of Experimental Medicine, 1994, 179, 533-540.	8.5	212
62	The cancer antigenome. EMBO Journal, 2012, 32, 194-203.	7.8	208
63	Peptide translocation by variants of the transporter associated with antigen processing. Science, 1993, 262, 2059-2063.	12.6	199
64	Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function. Journal of Immunology, 2010, 184, 4936-4946.	0.8	196
65	Bioactive and nuclease-resistant L-DNA ligand of vasopressin. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 11285-11290.	7.1	194
66	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nature Medicine, 2021, 27, 256-263.	30.7	190
67	Tumor organoidâ€“T-cell coculture systems. Nature Protocols, 2020, 15, 15-39.	12.0	189
68	Expression of the Serpin Serine Protease Inhibitor 6 Protects Dendritic Cells from Cytotoxic T Lymphocyteâ€“Induced Apoptosis. Journal of Experimental Medicine, 2001, 194, 657-668.	8.5	187
69	Simultaneous Detection of Circulating Autoreactive CD8+ T-Cells Specific for Different Islet Cellâ€“Associated Epitopes Using Combinatorial MHC Multimers. Diabetes, 2010, 59, 1721-1730.	0.6	187
70	Differentiation of cytomegalovirus-specific CD8+ T cells in healthy and immunosuppressed virus carriers. Blood, 2001, 98, 754-761.	1.4	186
71	Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19078-19083.	7.1	183
72	Antigen Bias in T Cell Cross-Priming. Science, 2004, 304, 1314-1317.	12.6	179

#	Article	IF	Citations
73	Intravital Microscopy Through an Abdominal Imaging Window Reveals a Pre-Micrometastasis Stage During Liver Metastasis. Science Translational Medicine, 2012, 4, 158ra145.	12.4	178
74	TIL therapy broadens the tumor-reactive CD8⁺T cell compartment in melanoma patients. OncoImmunology, 2012, 1, 409-418.	4.6	171
75	High-throughput identification of antigen-specific TCRs by TCR gene capture. Nature Medicine, 2013, 19, 1534-1541.	30.7	166
76	One naive T cell, multiple fates in CD8+ T cell differentiation. Journal of Experimental Medicine, 2010, 207, 1235-1246.	8.5	162
77	Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. Cell, 2019, 178, 585-599.e15.	28.9	162
78	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nature Medicine, 2021, 27, 1250-1261.	30.7	159
79	Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPÎ± axis and a target for cancer immunotherapy. Nature Medicine, 2019, 25, 612-619.	30.7	156
80	A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nature Medicine, 2005, 11, 899-904.	30.7	153
81	Acquired and intrinsic resistance in cancer immunotherapy. Molecular Oncology, 2014, 8, 1132-1139.	4.6	153
82	Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2657-2662.	7.1	150
83	Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3825-3830.	7.1	150
84	The Branching Point in Erythro-Myeloid Differentiation. Cell, 2015, 163, 1655-1662.	28.9	146
85	Dissection of T-cell Antigen Specificity in Human Melanoma. Cancer Research, 2012, 72, 1642-1650.	0.9	137
86	Tumor Rejection Induced by CD70-mediated Quantitative and Qualitative Effects on Effector CD8+ T Cell Formation. Journal of Experimental Medicine, 2004, 199, 1595-1605.	8.5	136
87	Recruitment of Antigen-Specific CD8 ⁺ T Cells in Response to Infection Is Markedly Efficient. Science, 2009, 325, 1265-1269.	12.6	133
88	Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nature Protocols, 2012, 7, 891-902.	12.0	131
89	T Cell Fate at the Single-Cell Level. Annual Review of Immunology, 2016, 34, 65-92.	21.8	131
90	Biomarkers in Cancer Immunotherapy. Cancer Cell, 2015, 27, 12-14.	16.8	130

#	Article	IF	Citations
91	Pairing of <scp>T</scp>â€cell receptor chains via emulsion <scp>PCR</scp>. European Journal of Immunology, 2013, 43, 2507-2515.	2.9	126
92	Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission. Journal of Clinical Oncology, 2012, 30, e7-e10.	1.6	119
93	Selective Expansion of Cross-Reactive Cd8+ Memory T Cells by Viral Variants. Journal of Experimental Medicine, 1999, 190, 1319-1328.	8.5	110
94	Dissecting T cell lineage relationships by cellular barcoding. Journal of Experimental Medicine, 2008, 205, 2309-2318.	8.5	107
95	Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. Nature Communications, 2019, 10, 766.	12.8	99
96	Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nature Communications, 2021, 12, 7348.	12.8	96
97	Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. European Journal of Immunology, 1991, 21, 2963-2970.	2.9	95
98	Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood, 2007, 110, 3564-3572.	1.4	95
99	Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features. Nature Communications, 2021, 12, 2593.	12.8	94
100	Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. Molecular Therapy, 2015, 23, 1541-1550.	8.2	93
101	Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy. Cancer Discovery, 2021, 11, 2602-2619.	9.4	90
102	Changing T cell specificity by retroviral T cell receptor display. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 14578-14583.	7.1	89
103	Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-Î³. Nature Cancer, 2020, 1, 291-301.	13.2	89
104	Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11583-11588.	7.1	86
105	High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. OncoImmunology, 2014, 3, e28836.	4.6	85
106	T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptideâ€“MHC complexes. Nature Biotechnology, 2018, 36, 1191-1196.	17.5	85
107	The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues. Nature Reviews Immunology, 2022, 22, 283-293.	22.7	85
108	Modular Nucleic Acid Assembled p/MHC Microarrays for Multiplexed Sorting of Antigen-Specific T Cells. Journal of the American Chemical Society, 2009, 131, 9695-9703.	13.7	84

#	Article	IF	Citations
109	Differential Kinetics of Antigen-Specific CD4+ and CD8+ T Cell Responses in the Regression of Retrovirus-Induced Sarcomas. Journal of Immunology, 2002, 169, 3191-3199.	0.8	82
110	Epstein-Barr Virus gp42 Is Posttranslationally Modified To Produce Soluble gp42 That Mediates HLA Class II Immune Evasion. Journal of Virology, 2005, 79, 841-852.	3.4	82
111	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. , 2020, 8, e000848.		79
112	In situ detection of virus- and tumor-specific T-cell immunity. Nature Medicine, 2000, 6, 1056-1060.	30.7	78
113	Apoptosis Threshold Set by Noxa and Mcl-1 after T Cell Activation Regulates Competitive Selection of High-Affinity Clones. Immunity, 2010, 32, 754-765.	14.3	78
114	Induction of neoantigen-reactive T cells from healthy donors. Nature Protocols, 2019, 14, 1926-1943.	12.0	78
115	Systemic T cell expansion during localized viral infection. European Journal of Immunology, 1999, 29, 1168-1174.	2.9	76
116	CD29 identifies IFN-Î³â€“producing human CD8⁺T cells with an increased cytotoxic potential. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6686-6696.	7.1	76
117	Redundancy of Direct Priming and Cross-Priming in Tumor-Specific CD8+ T Cell Responses. Journal of Immunology, 2001, 167, 3577-3584.	0.8	75
118	A committed tissue-resident memory T cell precursor within the circulating CD8+ effector T cell pool. Journal of Experimental Medicine, 2020, 217, .	8.5	72
119	Development of Adoptive Cell Therapy for Cancer: A Clinical Perspective. Human Gene Therapy, 2010, 21, 665-672.	2.7	71
120	Enhanced Immunogenicity of HPV 16 E7 Fusion Proteins in DNA Vaccination. Virology, 2002, 294, 47-59.	2.4	69
121	Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy. Cancer Cell, 2015, 28, 11-13.	16.8	69
122	Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors. JAMA Oncology, 2016, 2, 1490.	7.1	68
123	Enrichment of an Antigen-Specific T Cell Response by Retrovirally Transduced Human Dendritic Cells. Cellular Immunology, 1999, 195, 10-17.	3.0	67
124	Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. Journal of Controlled Release, 2010, 141, 234-240.	9.9	67
125	Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. OncoImmunology, 2012, 1, 609-617.	4.6	67
126	Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells. Cancer Immunology Research, 2019, 7, 552-558.	3.4	67

#	Article	IF	Citations
127	Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. Journal of Autoimmunity, 2011, 37, 151-159.	6.5	66
128	Subtle CXCR3-Dependent Chemotaxis of CTLs within Infected Tissue Allows Efficient Target Localization. Journal of Immunology, 2015, 195, 5285-5295.	0.8	66
129	MHC multimer technology: current status and future prospects. Current Opinion in Immunology, 2005, 17, 428-433.	5.5	65
130	Cellular barcoding: A technical appraisal. Experimental Hematology, 2014, 42, 598-608.	0.4	65
131	Neoantigens encoded in the cancer genome. Current Opinion in Immunology, 2016, 41, 98-103.	5.5	65
132	The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase. PLoS ONE, 2009, 4, e6910.	2.5	64
133	Specificity and affinity motifs for Grb2 SH2-ligand interactions. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8524-8529.	7.1	63
134	T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model. Journal of Immunotherapy, 2008, 31, 1-6.	2.4	63
135	Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients. ELife, 2015, 4, .	6.0	63
136	Are MHC-bound peptides a nuisance for positive selection?. Immunity, 1994, 1, 721-723.	14.3	62
137	Targeting self-antigens through allogeneic TCR gene transfer. Blood, 2006, 108, 870-877.	1.4	61
138	BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Reports, 2016, 16, 263-277.	6.4	61
139	RNAi-mediated TCR Knockdown Prevents Autoimmunity in Mice Caused by Mixed TCR Dimers Following TCR Gene Transfer. Molecular Therapy, 2014, 22, 1983-1991.	8.2	59
140	<scp>TCR</scp> repertoires of intratumoral Tâ€cell subsets. Immunological Reviews, 2014, 257, 72-82.	6.0	59
141	Tissue patrol by resident memory CD8+ T cells in human skin. Nature Immunology, 2019, 20, 756-764.	14.5	59
142	Tracing and characterization of the low-avidity self-specific T cell repertoire. European Journal of Immunology, 2000, 30, 1458-1468.	2.9	58
143	TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunology, Immunotherapy, 2009, 58, 809-822.	4.2	58
144	Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules. Journal of Immunology, 2015, 195, 4085-4095.	0.8	58

#	Article	IF	Citations
145	Discovering naturally processed antigenic determinants that confer protective T cell immunity. Journal of Clinical Investigation, 2013, 123, 1976-1987.	8.2	58
146	Regulatory role of CD19 molecules in B-cell activation and differentiation. Cellular Immunology, 1989, 118, 368-381.	3.0	57
147	Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cellâ€"Mediated Targeting of Carcinoembryonic Antigen. Cancer Research, 2008, 68, 8446-8455.	0.9	57
148	Î±Î² T Cell Receptor Transfer to Î³Î´ T Cells Generates Functional Effector Cells without Mixed TCR Dimers In Vivo. Journal of Immunology, 2009, 182, 164-170.	0.8	57
149	An Early HIV Mutation within an HLA-B*57-Restricted T Cell Epitope Abrogates Binding to the Killer Inhibitory Receptor 3DL1. Journal of Virology, 2011, 85, 5415-5422.	3.4	57
150	CD8+ T cell tolerance and cancer immunotherapy. Journal of Immunotherapy, 2003, 26, 1-11.	2.4	55
151	Immunological tumor destruction in a murine melanoma model by targeted LTÎ± independent of secondary lymphoid tissue. Cancer Immunology, Immunotherapy, 2008, 57, 85-95.	4.2	54
152	Optimization of Intradermal Vaccination by DNA Tattooing in Human Skin. Human Gene Therapy, 2009, 20, 181-189.	2.7	54
153	Manufacture of Gene-Modified Human T-Cells with a Memory Stem/Central Memory Phenotype. Human Gene Therapy Methods, 2014, 25, 277-287.	2.1	54
154	Quorum Regulation via Nested Antagonistic Feedback Circuits Mediated by the Receptors CD28 and CTLA-4 Confers Robustness to T Cell Population Dynamics. Immunity, 2020, 52, 313-327.e7.	14.3	54
155	Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity. Cancer Immunology Research, 2019, 7, 670-682.	3.4	53
156	Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice. Virology, 2006, 352, 157-168.	2.4	52
157	Requirements for Effective Antitumor Responses of TCR Transduced T Cells. Journal of Immunology, 2008, 181, 5128-5136.	0.8	52
158	High-Throughput T-Cell Epitope Discovery Through MHC Peptide Exchange. Methods in Molecular Biology, 2009, 524, 383-405.	0.9	52
159	Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses. European Journal of Immunology, 1992, 22, 3013-3020.	2.9	51
160	Mapping the life histories of T cells. Nature Reviews Immunology, 2010, 10, 621-631.	22.7	50
161	Junctional Biases in the Naive TCR Repertoire Control the CTL Response to an Immunodominant Determinant of HSV-1. Immunity, 2000, 12, 547-556.	14.3	49
162	Effective Postexposure Treatment of Retrovirus-Induced Disease with Immunostimulatory DNA Containing CpG Motifs. Journal of Virology, 2002, 76, 11397-11404.	3.4	49

#	Article	IF	Citations
163	Preclinical development of T cell receptor gene therapy. Current Opinion in Immunology, 2009, 21, 209-214.	5.5	48
164	On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma Patients. Clinical Cancer Research, 2004, 10, 4754-4760.	7.0	47
165	RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunology, Immunotherapy, 2010, 59, 1173-1183.	4.2	47
166	Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine, 2008, 26, 3346-3351.	3.8	45
167	Transporters from H-2b, H-2d, H-2s, H-2k, and H-2g7 (NOD/Lt) haplotype translocate similar sets of peptides.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 13004-13008.	7.1	44
168	Functional Human Antigen-Specific T Cells Produced In Vitro Using Retroviral T Cell Receptor Transfer into Hematopoietic Progenitors. Journal of Immunology, 2007, 179, 4959-4968.	0.8	44
169	GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 429-438.	4.3	44
170	Behavior and Function of Tissue-Resident Memory T cells. Advances in Immunology, 2012, 114, 203-216.	2.2	44
171	Preferred size of peptides that bind to H-2 Kb is sequence dependent. European Journal of Immunology, 1992, 22, 1603-1608.	2.9	43
172	Analysis of Autoreactive CD4 T Cells in Experimental Autoimmune Encephalomyelitis after Primary and Secondary Challenge Using MHC Class II Tetramers. Journal of Immunology, 2004, 172, 2878-2884.	0.8	43
173	CD4 memory T cells survive and proliferate but fail to differentiate in the absence of CD40. Journal of Experimental Medicine, 2006, 203, 897-906.	8.5	43
174	Human Telomerase Reverse Transcriptase-Transduced Human Cytotoxic T Cells Suppress the Growth of Human Melanoma in Immunodeficient Mice. Cancer Research, 2004, 64, 2153-2161.	0.9	42
175	Prospects and Limitations of T Cell Receptor Gene Therapy. Current Gene Therapy, 2011, 11, 276-287.	2.0	42
176	Can the Low-Avidity Self-Specific T Cell Repertoire Be Exploited for Tumor Rejection?. Journal of Immunology, 2002, 168, 651-660.	0.8	41
177	Generation of Peptide MHC Class I Monomers and Multimers Through Ligand Exchange. Current Protocols in Immunology, 2009, 87, Unit 18.16.	3.6	41
178	Low-Avidity Self-Specific T Cells Display a Pronounced Expansion Defect That Can Be Overcome by Altered Peptide Ligands. Journal of Immunology, 2001, 167, 3818-3828.	0.8	40
179	Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunology, Immunotherapy, 2011, 60, 1359-1371.	4.2	40
180	Blockade of TGF-Î² Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer. Journal of Immunology, 2013, 191, 3232-3239.	0.8	40

#	Article	IF	Citations
181	Altered Peptide Ligands Revisited: Vaccine Design through Chemically Modified HLA-A2â€“Restricted T Cell Epitopes. Journal of Immunology, 2014, 193, 4803-4813.	0.8	40
182	Determining Lineage Pathways from Cellular Barcoding Experiments. Cell Reports, 2014, 6, 617-624.	6.4	40
183	Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 403-408.	7.1	40
184	Comprehensive analysis of cutaneous and uveal melanoma liver metastases. , 2020, 8, e001501.		40
185	Polymorphisms in pockets of major histocompatibility complex class I molecules influence peptide preference.. Journal of Experimental Medicine, 1993, 177, 1713-1721.	8.5	39
186	Generation of T Cell Help through a MHC Class I-Restricted TCR. Journal of Immunology, 2006, 177, 976-982.	0.8	39
187	TCR Gene Therapy of Spontaneous Prostate Carcinoma Requires In Vivo T Cell Activation. Journal of Immunology, 2008, 181, 2563-2571.	0.8	39
188	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNÎ³ Signaling. Cancer Research, 2017, 77, 4562-4566.	0.9	39
189	A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product. European Journal of Immunology, 1992, 22, 1651-1654.	2.9	38
190	T-Cell Receptor Gene Therapy: Critical Parameters for Clinical Success. Journal of Investigative Dermatology, 2011, 131, 1806-1816.	0.7	38
191	Human cancer regression antigens. Current Opinion in Immunology, 2013, 25, 284-290.	5.5	38
192	Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ TÂcells. Cell Reports, 2021, 37, 110013.	6.4	38
193	Temporal Effects of Gamma Interferon Deficiency on the Course of Friend Retrovirus Infection in Mice. Journal of Virology, 2002, 76, 2225-2232.	3.4	37
194	In Vivo Antigen Stability Affects DNA Vaccine Immunogenicity. Journal of Immunology, 2007, 179, 2126-2133.	0.8	37
195	Assembly and intracellular transport of major histocompatibility complex molecules. Current Opinion in Cell Biology, 1991, 3, 601-609.	5.4	36
196	Synthetic peptide libraries in the determination of T cell epitopes and peptide binding specificity of class I molecules. European Journal of Immunology, 1992, 22, 1405-1412.	2.9	36
197	Optimizing the Efficacy of Epitope-Directed DNA Vaccination. Journal of Immunology, 2002, 168, 4998-5004.	0.8	36
198	High-Throughput Identification of Potential Minor Histocompatibility Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations. PLoS ONE, 2011, 6, e22523.	2.5	36

#	Article	IF	Citations
199	The descent of memory T cells. Annals of the New York Academy of Sciences, 2011, 1217, 139-153.	3.8	35
200	UV-Induced Ligand Exchange in MHC Class I Protein Crystals. Journal of the American Chemical Society, 2009, 131, 12298-12304.	13.7	34
201	Parallel InÂVivo and InÂVitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition. Cell Reports, 2014, 9, 1375-1386.	6.4	34
202	An Inducible Caspase 9 Safety Switch Can Halt Cell Therapy-Induced Autoimmune Disease. Journal of Immunology, 2008, 180, 6365-6373.	0.8	33
203	SLFN11 can sensitize tumor cells towards IFN-Î³-mediated T cell killing. PLoS ONE, 2019, 14, e0212053.	2.5	33
204	Adoptive transfer of T-cell immunity. Trends in Immunology, 2002, 23, 264-269.	6.8	32
205	Characterization of CD8+ T-cell response in acute and resolved hepatitis A virus infection. Journal of Hepatology, 2011, 54, 201-208.	3.7	32
206	Rational Design of DNA Vaccines for the Induction of Human Papillomavirus Type 16 E6- and E7-Specific Cytotoxic T-Cell Responses. Human Gene Therapy, 2012, 23, 1301-1312.	2.7	32
207	Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. International Journal of Cancer, 2011, 129, 397-406.	5.1	31
208	Antigenâ€specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. European Journal of Immunology, 2016, 46, 1351-1360.	2.9	31
209	Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.. Journal of Clinical Oncology, 2018, 36, 1012-1012.	1.6	31
210	Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage. Journal of Immunology, 2015, 195, 4075-4084.	0.8	30
211	T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFÎ± Expression and Empower Adoptive Cell Therapy for Solid Tumors. Cancer Research, 2017, 77, 658-671.	0.9	30
212	Replicative history marks transcriptional and functional disparity in the CD8+ T cell memory pool. Nature Immunology, 2022, 23, 791-801.	14.5	30
213	MHC-based detection of antigen-specific CD8+ T cell responses. Cancer Immunology, Immunotherapy, 2010, 59, 1425-1433.	4.2	29
214	Single cell behavior in T cell differentiation. Trends in Immunology, 2014, 35, 170-177.	6.8	28
215	Class I Major Histocompatibility Complexes Loaded by a Periodate Trigger. Journal of the American Chemical Society, 2009, 131, 12305-12313.	13.7	27
216	Mixed functional characteristics correlating with <scp>TCR</scp>â€ligand k_{off}â€rate of <scp>MHC</scp>â€tetramer reactive <scp>T</scp> cells within the naive <scp>T</scp>â€cell repertoire. European Journal of Immunology, 2013, 43, 3038-3050.	2.9	27

#	Article	IF	Citations
217	DNA Vaccines and Intradermal Vaccination by DNA Tattooing. Current Topics in Microbiology and Immunology, 2010, 351, 221-250.	1.1	26
218	Synthetic vehicles for DNA vaccination. Journal of Drug Targeting, 2010, 18, 1-14.	4.4	26
219	Prospects and Limitations of T Cell Receptor Gene Therapy. Current Gene Therapy, 2005, 5, 583-593.	2.0	25
220	Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection. Nature Communications, 2019, 10, 4986.	12.8	24
221	Optimization of intradermal vaccination by DNA tattooing in human skin. Human Gene Therapy, 2008, 20, 081125111040089.	2.7	24
222	Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnology, 2007, 7, 2.	3.3	23
223	Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: Updated data from the OpACIN trial and first immunological analyses.. Journal of Clinical Oncology, 2017, 35, 9586-9586.	1.6	23
224	A soluble, single-chain Kd molecule produced by yeast selects a peptide repertoire indistinguishable from that of cell-surface-associated Kd. European Journal of Immunology, 1993, 23, 1776-1783.	2.9	22
225	Long-Term Functionality of TCR-Transduced T Cells In Vivo. Journal of Immunology, 2008, 180, 6536-6543.	0.8	22
226	Adoptive T cell therapy of cancer. Current Opinion in Immunology, 2009, 21, 187-189.	5.5	22
227	Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia, 2010, 24, 1901-1909.	7.2	22
228	Development of a Hypersensitive Periodateâ€Cleavable Amino Acid that is Methionineâ€•and Disulfideâ€Compatible and its Application in MHC Exchange Reagents for T Cell Characterisation. ChemBioChem, 2013, 14, 123-131.	2.6	22
229	Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. Journal of Experimental Medicine, 2016, 213, 2333-2348.	8.5	22
230	Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression. Blood, 2012, 119, 798-804.	1.4	21
231	A liquid biopsy for cancer immunotherapy. Nature Medicine, 2016, 22, 340-341.	30.7	21
232	Assessing T lymphocyte function and differentiation by genetically encoded reporter systems. Trends in Immunology, 2015, 36, 392-400.	6.8	20
233	Cancer immunotherapy. Current Opinion in Immunology, 2013, 25, 259-260.	5.5	19
234	The Impact of Self-Tolerance on the Polyclonal CD8+ T Cell Repertoire. Journal of Immunology, 2004, 172, 2324-2331.	0.8	18

#	Article	IF	Citations
235	Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines. Gene Therapy, 2015, 22, 560-567.	4.5	17
236	HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia. Cancer Immunology, Immunotherapy, 2017, 66, 1163-1173.	4.2	17
237	CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function. Cancer Immunology Research, 2021, 9, 999-1007.	3.4	17
238	Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).. Journal of Clinical Oncology, 2019, 37, 2575-2575.	1.6	17
239	Shift from Systemic to Site-Specific Memory by Tumor-Targeted IL-2. Journal of Immunology, 2004, 172, 5843-5850.	0.8	16
240	The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunology, Immunotherapy, 2013, 62, 489-501.	4.2	16
241	HLA Micropolymorphisms Strongly Affect Peptideâ€“MHC Multimerâ€“Based Monitoring of Antigen-Specific CD8+ T Cell Responses. Journal of Immunology, 2014, 192, 641-648.	0.8	16
242	Direct Ex Vivo Detection of HLA-DR3â€“Restricted Cytomegalovirus- and Mycobacterium tuberculosisâ€“Specific CD4+ T Cells. Human Immunology, 2005, 66, 950-961.	2.4	15
243	Breadth and Dynamics of HLA-A2â€“ and HLA-B7â€“Restricted CD8+ T Cell Responses against Nonstructural Viral Proteins in Acute Human Tick-Borne Encephalitis Virus Infection. ImmunoHorizons, 2018, 2, 172-184.	1.8	15
244	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	15
245	Dissection of cytotoxic and helper T cell responses. Cellular and Molecular Life Sciences, 2005, 62, 2695-2710.	5.4	14
246	Technologies for MHC class I immunoproteomics. Journal of Proteomics, 2010, 73, 1945-1953.	2.4	14
247	Reproducibility of Illumina platform deep sequencing errors allows accurate determination of DNA barcodes in cells. BMC Bioinformatics, 2016, 17, 151.	2.6	14
248	Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines. Current Opinion in Immunology, 2021, 69, 65-71.	5.5	14
249	Single-cell analysis of regions of interest (SCARI) using a photosensitive tag. Nature Chemical Biology, 2021, 17, 1139-1147.	8.0	13
250	Safety switches for adoptive cell therapy. Current Opinion in Immunology, 2022, 74, 190-198.	5.5	12
251	T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. Nature Biotechnology, 2022, 40, 488-498.	17.5	12
252	Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease. Blood, 2007, 109, 3830-3838.	1.4	11

#	Article	IF	Citations
253	Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer. JCO Precision Oncology, 2017, 1, 1-3.	3.0	11
254	Formation of Tissue-Resident CD8⁺ T-Cell Memory. Cold Spring Harbor Perspectives in Biology, 2021, 13, a038117.	5.5	11
255	HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial. , 2021, 9, e002547.		11
256	Intradermal Vaccination by DNA Tattooing. Methods in Molecular Biology, 2014, 1143, 131-140.	0.9	11
257	Accessory to murder. Nature, 1999, 398, 26-27.	27.8	10
258	Transposon leads to contamination of clinical pDNA vaccine. Vaccine, 2013, 31, 3274-3280.	3.8	10
259	Lipopolysaccharide contamination in intradermal DNA vaccination: Toxic impurity or adjuvant?. International Journal of Pharmaceutics, 2010, 390, 32-36.	5.2	9
260	A mouse model that is immunologically tolerant to reporter and modifier proteins. Communications Biology, 2020, 3, 273.	4.4	9
261	Immunotherapeutic strategies: the melanoma example. Immunotherapy, 2009, 1, 679-690.	2.0	9
262	QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment. OncoImmunology, 2022, 11, 2049486.	4.6	9
263	MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial. Immuno-Oncology Technology, 2022, 15, 100089.	0.3	9
264	Tumors hijack fetal enzyme, escape killer T cells. Nature Medicine, 2003, 9, 1253-1254.	30.7	8
265	Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials. Cancer Research, 2020, 80, 3412-3412.	0.9	8
266	Repertoire-Determining Role of Peptide in the Positive Selection of CD8+ T cells. Immunological Reviews, 1993, 135, 157-182.	6.0	7
267	Circumventing T-cell Tolerance to Tumour Antigens. Biologicals, 2001, 29, 277-283.	1.4	7
268	Segmentation of occluded hematopoietic stem cells from tracking. , 2014, 2014, 5510-3.		6
269	Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells. Cancer Immunology Research, 2020, 8, 685-697.	3.4	6
270	Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer. Cancer Research, 2008, 68, 2455-2462.	0.9	5

#	Article	IF	Citations
271	Microbead-Assisted Retroviral Transduction for Clinical Application. Human Gene Therapy, 2010, 21, 1335-1342.	2.7	5
272	SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens. Blood, 2008, 112, 814-814.	1.4	5
273	An atlas of intratumoral T cells. Science, 2021, 374, 1446-1447.	12.6	5
274	CMV-specific CD8pos T lymphocyte differentiation in latent CMV infection. Transplantation Proceedings, 2001, 33, 1802-1803.	0.6	4
275	Vaccine leads to memory loss. Nature Medicine, 2007, 13, 248-250.	30.7	4
276	pMHC Multiplexing Strategy to Detect High Numbers of T Cell Responses in Parallel. Methods in Molecular Biology, 2017, 1514, 93-101.	0.9	4
277	Immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to (salvage) surgery in advanced or recurrent head and neck carcinoma, IMCISION, an investigator-initiated phase-Ib/II trial (N16IMC, NCT03003637).. Journal of Clinical Oncology, 2018, 36, e18020-e18020.	1.6	3
278	Differentiation of CMV-specific CD8POS T lymphocytes in primary CMV infection after renal transplantation. Transplantation Proceedings, 2001, 33, 3630.	0.6	2
279	Gene Transfer of MHC-Restricted Receptors. , 2005, 109, 201-214.		2
280	Generating CTL by HLA transplant. Blood, 2004, 103, 4381-4382.	1.4	2
281	Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes. Results in Immunology, 2012, 2, 88-96.	2.2	2
282	Barriers to chimerism after major histocompatibility complex-mismatched stem cell transplantation: A potential role forÂheterologousÂimmunity. Experimental Hematology, 2014, 42, 753-760.	0.4	2
283	A Traceless Selection: Counter-selection System That Allows Efficient Generation of Transposon and CRISPR-modified T-cell Products. Molecular Therapy - Nucleic Acids, 2016, 5, e298.	5.1	2
284	Labeling and tracking of immune cells in ex vivo human skin. Nature Protocols, 2021, 16, 791-811.	12.0	2
285	Systemic T cell expansion during localized viral infection. European Journal of Immunology, 1999, 29, 1168-1174.	2.9	2
286	Multimodular Optimization of Chemically Regulated T Cell Switches Demonstrates Flexible and Interchangeable Nature of Immune Cell Signaling Domains. Human Gene Therapy, 2021, 32, 1029-1043.	2.7	2
287	Diverse and heritable lineage imprinting of early hematopoietic progenitors. Experimental Hematology, 2013, 41, S13.	0.4	1
288	Enhanced immunogenicity of MHC class I-restricted tumor-associated altered peptide ligands. Molecular Immunology, 2012, 51, 33-34.	2.2	0

#	Article	IF	Citations
289	TCR-Engineered T cells. , 2014, , 49-82.		0
290	Combining cellular barcoding and mathematical modeling to infer the structure of the hematopoietic pathway. Experimental Hematology, 2014, 42, S56.	0.4	0
291	Common myeloid progenitors are made up of distinct subpopulations that either yield erythrocytes or myeloid cells. Experimental Hematology, 2015, 43, S88.	0.4	0
292	Editorial overview: Cancer immunology: genomics & biomarkers: Cancer immunity through the prism of genomics and proteomics. Current Opinion in Immunology, 2016, 41, ix-x.	5.5	0
293	Ex vivo and in situ detection of tumor-specific T-cell immunity with MHC tetramers. , 2003, , 111-130.		0
294	How T Cells Single Out Tumor Cells: â€œAnd That Has Made All the Differenceâ€¦â€• , 2014, , 13-20.		0
295	Abstract 4704: Neo-antigen enriched TIL therapy mediates superior tumor eradication in a patient-derived xenograft model of human melanoma. , 2015, , .		0
296	Abstract PR11: Neo-antigen landscape dynamics during human melanoma-T cell interactions. , 2016, , .		0
297	Abstract IA04: T cell recognition and tumor resistance in human cancer. , 2016, , .		0
298	Abstract A009: Benchmarking the foreign antigen space of human malignancies. , 2016, , .		0
299	Abstract B044: Patient-specific immunotherapy through TCR gene transfer. , 2016, , .		0
300	Abstract IA24: T cell recognition and tumor resistance in human cancer. , 2017, , .		0
301	Abstract LB-291: Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. , 2017, , .		0
302	Benchmarking the Foreign Antigen Space of Human Malignancies. SSRN Electronic Journal, 0, , .	0.4	0
303	Abstract KN02: Keynote Lecture: T-cell recognition of human cancer. , 2018, , .		0
304	Abstract B54: Dissecting immune cell heterogeneity in human cancer by single-cell RNA-sequencing. , 2018, , .		0
305	Measuring T-cell avidity and enrichment using acoustic force-based technology.. Journal of Clinical Oncology, 2019, 37, e14010-e14010.	1.6	0
306	Abstract 3210: Strategies to improve the sensitivity and ranking ability of neoantigen prediction methods: Report on the results of the Tumor nEoantigen SeLection Alliance (TESLA). , 2020, , .		0

#	Article	IF	Citations
307	Abstract 5153: Measuring T-cell avidity and enrichment using an acoustic force based technology. , 2019, , .		0